May 27, 2021
Despite the remarkable research supporting regenerative medicine like Stem Cells and Exosomes, the FDA has decided to ban the use of these treatments in the US. Many argue that it is because big pharma is looking for a way to monopolies the treatment or effectively end the possibility of it because they have the ability to cure people, instead of keeping them dependent on pills forever, which results in loss revenue for big pharma companies. Besides the obstacles created by the business side of the medical realm, there is a ton of misinformation surrounding the ethics of treatments like Stem Cells. For example, those that are not in the know are under the impression that stem cells are recruited from babies or fetuses that result in pregnancy complications. This couldn't be further from the truth. To get to the bottom of it, I invited Founder, President & Chief Scientific Officer of Neobiosis, Dr. Ian White, onto the show. Enjoy!
About
Our Guest:
Dr. White. is an expert in the field of regenerative medicine and
stem cell biology with over 20 years’ experience working in
academia and industry. Dr. White received his B.S. from Liverpool
John Moores University and his M.S. from the famed Liverpool School
of Tropical Medicine in England prior to being hired at Dartmouth
College in the United States to study the genetics of gamete
biology. In August of 2000 Dr. White was recruited to Harvard
University to work with hematopoietic stem cells (HSCs) and immune
cell biology under the mentorship of the world-renowned Dr. Laurie
Glimcher, where he co-authored several peer-reviewed scientific
publications. Dr. White went on to receive his Ph.D. from the
Ansary Stem Cell Institute, division of Regenerative Medicine at
Cornell University under the guidance of Howard Hughes investigator
Dr. Shahin Rafii. During this time Dr. White developed an in vitro
method for culture expanding autologous HSCs in an artificial
vascular niche for the treatment of cancer patients who have
undergone bone marrow ablation following chemo- or
radio-therapy.
This technology has since gone on to be commercialized by Cornell and the company, Angiocrine, LLC, has become one of the top two HSC expansion companies in the US. Following the completion of his Ph.D., Dr. White spent time as a post-doctoral research scientist in the embryonic stem cell (ESC) laboratory of Dr. Stephen Dalton, whose pioneering work led to the inclusion of c-myc as one of the four factors used by Nobel award winning Dr. Shinya Yamanaka in the generation of induced pluripotent stem cells (iPSCs). Subsequently, Dr. White relocated to the Interdisciplinary Stem Cell Institute at the University of Miami Miller School of Medicine. Dr. White published ground-breaking research in the field of regenerative medicine alongside Dr. Joshua Hare, including a book chapter on the use of Mesenchymal Stem Cells (MSCs) in cardiac regeneration. In 2015, Dr. White’s work on the regeneration of the heart was featured on the cover of Circulation Research, one of the top peer-reviewed journals for cardiovascular medicine in the world. In 2016. Dr. White was honored with an award for the “Best Manuscript” by the American Heart Association for this work, which highlighted the role of peripheral nerves in cardiac regeneration. Dr. White has lectured and published extensively in the field of stem cell biology, clinical stem cell applications and regenerative medicine.
To connect with Dr. Ian White, visit: https://neobiosis.com